Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TLD domain-containing protein 2 (TLDC2) is a small eukaryotic protein primarily composed of the TLDc domain, which is structurally characterized by a globular fold with a beta-sandwich and surrounding helices[1]. TLDC2 is expressed mostly in the kidney's B-intercalated cells and some non-A non-B intercalated cells. It interacts with V-ATPase, influencing its assembly and function, thereby regulating acid-base homeostasis, particularly bicarbonate secretion during renal defense against alkalosis[2][5]. TLDC2 and its family members have a well-supported role in protection from oxidative stress, by influencing the expression and activity of antioxidant systems[1][4]. While other members of the family have been implicated in neurological disorders, TLDC2 itself has not been linked directly to human disease but is essential for proper kidney function and systemic acid-base balance[2][5].
no approved drugs or agents known to target this molecule; mechanistic studies show TLDC2 interacts with and can induce disassembly of V-ATPase, regulating proton transport and thus cellular acid-base balance[2][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TLD domain-containing protein 2 (TLDC2).